共 50 条
- [1] Nivolumab plus ipilimumab in melanoma brain metastasesLANCET ONCOLOGY, 2022, 23 (02): : E54 - E54Tawbi, Hussein A.Eroglu, ZeynepAnders, Carey K.Margolin, Kim
- [2] Retrospective individual case reports on the treatment of patients with advanced BRAFV600-mutant malignant melanoma with encorafenib plus binimetinib (REMINISCENCE): focus on patients with brain metastasesJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 79 - 80Debus, D.Rohrer, P.Grote, C.Kaehler, K. C.Koch, L.Reichenbach, F.Terheyden, P.Nguyen, V. A.
- [3] A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Gonzalez, MariaHong, Angela M.Carlino, Matteo S.Atkinson, VictoriaWang, WeiLo, SerigneBrown, Michael PaulFoote, Matthew C.Pinkham, Mark B.Le, HienRoos, Daniel E.Osorio, MonicaHaghighi, NedaKok, DavidPostow, Michael A.McArthur, Grant A.Menzies, Alexander M.Long, Georgina V.
- [4] The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastasesTRANSLATIONAL ONCOLOGY, 2022, 22Fukumoto, TakeshiHorita, Nobuyuki
- [5] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 212 - +Ascierto, Paolo A. A.Mandala, MarioFerrucci, Pier FrancessoGuidoboni, MassimoRutkowski, PiotrFerraresi, VirginiaArance, AnaGuida, MicheleMaiello, EvaristoGogas, HelenRichtig, ErikaFierro, Maria TeresaLebbe, CelesteHelgadottir, HildurQueirolo, PaolaSpagnolo, FrancescoTucci, MarcoDel Vecchio, MicheleGonzales Cao, MariaMinisini, Alessandro MarcoDe Placido, SabinoSanmamed, Miguel F. F.Mallardo, DomenicoCurvietto, MarcelloMelero, IgnacioPalmieri, GiuseppeGrimaldi, Antonio M.Giannarelli, DianaDummer, ReinhardSileni, Vanna Chiarion
- [6] Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanomaANNALS OF ONCOLOGY, 2023, 34 : S700 - S700Schadendorf, D.Dummer, R.Ribas, A.Robert, C.Sullivan, R. J.King, A.Polli, A.di Pietro, A.Ascierto, P. A.
- [7] Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study designFUTURE ONCOLOGY, 2022, 18 (07) : 781 - 791Riely, Gregory J.Ahn, Myung-JuFelip, EnriquetaRamalingam, Suresh S.Smit, Egbert F.Tsao, Anne S.Alcasid, AnnUsari, TizianaWissel, Paul S.Wilner, Keith D.Johnson, Bruce E.
- [8] BAYONET trial: A multicenter phase II trial of staged combination with encorafenib plus binimetinib plus cetuximab following encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS271 - TPS271Matsubara, YukiBando, HideakiKotani, DaisukeKagawa, YoshinoriHarada, KazuakiOsumi, HirokiIzawa, NaokiKawakami, TakeshiBoku, ShogenMatsumoto, ToshihikoWakabayashi, MasashiYoshino, Takayuki
- [9] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trialANNALS OF ONCOLOGY, 2020, 31 : S734 - S734Di Giacomo, A. M.Sileni, V. ChiarionDel Vecchio, M.Ferrucci, P. F.Guida, M.Quaglino, P.Guidoboni, M.Marchetti, P.Cutaia, O.Amato, G.Gambale, E.Calabro, L.Valente, M.Danielli, R.Giannarelli, D.Mandala, M.Maio, M.
- [10] A phase II, open-label, randomized, multicenter trial of encorafenib plus binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS)ANNALS OF ONCOLOGY, 2019, 30 : 562 - 563Davies, M. A.Weber, J. S.Flaherty, K. T.McArthur, G. A.Reddy, M. B.Golden, A.Culbertson, J. L.Thomas, C. T.Tawbi, H. A.Long, G. V.